Li Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5526911/publications.pdf

Version: 2024-02-01

119	1,468	19	32
papers	citations	h-index	g-index
127	127	127	1928
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Impact of COVID-19 pandemic on STEMI undergoing primary PCI treatment in Beijing, China. American Journal of Emergency Medicine, 2022, 53, 68-72.	0.7	5
2	Systemic therapy in patients with metastatic $Xp11.2$ translocation renal cell carcinoma Journal of Clinical Oncology, 2022, 40, 341-341.	0.8	0
3	Clinical characteristics of patients with collecting duct carcinoma Journal of Clinical Oncology, 2022, 40, 297-297.	0.8	O
4	Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy. Melanoma Research, 2022, Publish Ahead of Print, .	0.6	4
5	Prognostic value of HER2 expression levels for upper tract urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 557-557.	0.8	5
6	Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 515-515.	0.8	24
7	Impact of different HER2 expression levels on the outcomes of second-line immunotherapy for metastatic urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 524-524.	0.8	1
8	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis., 2022, 10, e004036.		24
9	Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues. Journal of Viral Hepatitis, 2022, 29, 420-431.	1.0	6
10	Prevalence of post-traumatic stress disorder symptoms among patients with mental disorder during the COVID-19 pandemic. BMC Psychiatry, 2022, 22, 156.	1.1	5
11	Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 354-362.	0.9	4
12	Abiotrophia Defectiva as a Rare Cause of Mitral Valve Infective Endocarditis With Mesenteric Arterial Branch Pseudoaneurysm, Splenic Infarction, and Renal Infarction: A Case Report. Frontiers in Medicine, 2022, 9, 780828.	1.2	6
13	OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study. , 2022, 10, e004307.		13
14	Evaluation of Sampson equation for LDL-C in acute coronary syndrome patients: a Chinese population-based cohort study. Lipids in Health and Disease, 2022, 21, 39.	1.2	5
15	Wellens' syndrome: incidence, characteristics, and long-term clinical outcomes. BMC Cardiovascular Disorders, 2022, 22, 176.	0.7	13
16	An Evidence-Based Staging System for Mucosal Melanoma: A Proposal. Annals of Surgical Oncology, 2022, 29, 5221-5234.	0.7	15
17	ASO Visual Abstract: An Evidence-Based Staging System for Mucosal Melanoma: a Proposal. Annals of Surgical Oncology, 2022, , .	0.7	0
18	The association of Ki67 level and adjuvant treatment options in mucosal melanoma Journal of Clinical Oncology, 2022, 40, e21582-e21582.	0.8	0

#	Article	IF	CITATIONS
19	Phase Ib study of anlotinib in combination with anti-PD-L1 ab (TQB2450) in patients with advanced acral melanoma Journal of Clinical Oncology, 2022, 40, e21543-e21543.	0.8	0
20	A phase Ia/Ib study evaluating the safety and efficacy of intratumorally administrated OH2, an oncolytic herpes simplex virus 2, in unresected stage IIIC to IV melanoma patients Journal of Clinical Oncology, 2022, 40, e21537-e21537.	0.8	1
21	Analysis of overall survival (OS) and relapse-free-survival (RFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intralesional injection of OrienX010 in stage ⣠melanoma with liver metastases Journal of Clinical Oncology, 2022, 40, 9551-9551.	0.8	2
22	A phase I dose-escalation study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma and other solid tumors Journal of Clinical Oncology, 2022, 40, e14586-e14586.	0.8	0
23	Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 4518-4518.	0.8	12
24	A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM) Journal of Clinical Oncology, 2022, 40, 9508-9508.	0.8	5
25	Adjuvant temozolomide plus cisplatin versus high-dose interferon alpha-2b in resected mucosal melanoma: A randomized, multicenter, controlled, phase III trial Journal of Clinical Oncology, 2022, 40, 9578-9578.	0.8	2
26	The uric acid to albumin ratio: a novel predictor of long-term cardiac mortality in patients with unstable angina pectoris after percutaneous coronary intervention. Scandinavian Journal of Clinical and Laboratory Investigation, 2022, 82, 304-310.	0.6	8
27	A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 4519-4519.	0.8	15
28	Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma Journal of Clinical Oncology, 2022, 40, 4563-4563.	0.8	1
29	Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial Journal of Clinical Oncology, 2022, 40, 9512-9512.	0.8	2
30	Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 75.e1-75.e8.	0.8	9
31	Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy. Translational Oncology, 2021, 14, 100949.	1.7	6
32	A sex-stratified long-term clinical outcome analysis in coronary chronic total occlusion patients. Biology of Sex Differences, 2021, 12, 9.	1.8	3
33	Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2731-2740.	1.2	3
34	Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. Journal of Clinical Oncology, 2021, 39, 881-889.	0.8	37
35	The impact of successful chronic total occlusion percutaneous coronary intervention on long-term clinical outcomes in real world. BMC Cardiovascular Disorders, 2021, 21, 182.	0.7	2
36	Apatinib in combination with camrelizumab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic acral melanoma Journal of Clinical Oncology, 2021, 39, 9539-9539.	0.8	2

#	Article	IF	Citations
37	Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials. Frontiers in Oncology, 2021, 11, 639085.	1.3	6
38	Clinicopathologic features of $Xp11.2$ translocation renal cell carcinoma and its response to target therapy Journal of Clinical Oncology, 2021, 39, e16559-e16559.	0.8	0
39	A phase 2 clinical trial of neoadjuvant anti-PD-1 ab (Toripalimab) plus axitinib in resectable mucosal melanoma Journal of Clinical Oncology, 2021, 39, 9512-9512.	0.8	9
40	A phase Ib clinical trial of neoadjuvant OrienX010, an oncolytic virus, in combination with toripalimab in patients with resectable stage IIIb to stage IVM1a acral melanoma Journal of Clinical Oncology, 2021, 39, 9570-9570.	0.8	5
41	Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. European Journal of Cancer, 2021, 148, 297-306.	1.3	19
42	RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study Journal of Clinical Oncology, 2021, 39, 4534-4534.	0.8	10
43	Adjuvant radiotherapy plus systemic chemotherapy in resected head and neck mucosal melanoma Journal of Clinical Oncology, 2021, 39, e18042-e18042.	0.8	1
44	Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase randomized trial Journal of Clinical Oncology, 2021, 39, 9573-9573.	0.8	4
45	Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials. Frontiers in Immunology, 2021, 12, 691032.	2.2	10
46	Risk analysis of poor wound healing in forceps delivery. Journal of Obstetrics and Gynaecology Research, 2021, 47, 3509-3515.	0.6	0
47	Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. Frontiers in Oncology, 2021, 11, 720044.	1.3	9
48	Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma. European Journal of Cancer, 2021, 156, 83-92.	1.3	7
49	Urinary Alpha1-Microglobulin: A New Predictor for In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction. Medical Science Monitor, 2021, 27, e927958.	0.5	2
50	Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies. Frontiers in Pharmacology, 2021, 12, 747416.	1.6	0
51	Surgical Outcomes of Vaginal or Cervical Melanoma. Frontiers in Surgery, 2021, 8, 771160.	0.6	1
52	Activation of α7nAChR Protects Against Gastric Inflammation and Dysmotility in Parkinson's Disease Rats. Frontiers in Pharmacology, 2021, 12, 793374.	1.6	7
53	TAF and TDF attenuate liver fibrosis through NS5ATP9, TGFβ1/Smad3, and NF-κB/NLRP3 inflammasome signaling pathways. Hepatology International, 2020, 14, 145-160.	1.9	14
54	The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Frontiers in Oncology, 2020, 10, 546604.	1.3	15

#	Article	IF	Citations
55	Perinatal listeriosis patients treated at a maternity hospital in Beijing, China, from 2013–2018. BMC Infectious Diseases, 2020, 20, 601.	1.3	20
56	Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine, 2020, 55, 102755.	2.7	12
57	The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma. Annals of Surgical Oncology, 2020, 27, 3478-3485.	0.7	29
58	A Functional Synonymous Variant in <i>PDGFRA</i> Is Associated with Better Survival in Acral Melanoma. Journal of Cancer, 2020, 11, 2945-2956.	1.2	8
59	Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma Journal of Clinical Oncology, 2020, 38, 10007-10007.	0.8	11
60	A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma Journal of Clinical Oncology, 2020, 38, 10040-10040.	0.8	10
61	A first-in-human phase I/II study of HL-085, a MEK Inhibitor, in Chinese patients with NRASm advanced melanoma Journal of Clinical Oncology, 2020, 38, 10047-10047.	0.8	5
62	A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma Journal of Clinical Oncology, 2020, 38, e17113-e17113.	0.8	9
63	IBI310 monotherapy or in combination with sintilimab in patients with advanced melanoma: An open-label phase Ia/1b study Journal of Clinical Oncology, 2020, 38, e15111-e15111.	0.8	1
64	Phase II study of apatinib combined with temozolomide in advanced melanoma patients after failure of anti-PD-1 therapy Journal of Clinical Oncology, 2020, 38, e22043-e22043.	0.8	1
65	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. Clinical Cancer Research, 2019, 25, 6511-6523.	3.2	62
66	Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G ₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. Journal of Clinical Oncology, 2019, 37, 2987-2999.	0.8	126
67	Downregulated Dopamine Receptor 2 and Upregulated Corticotrophin Releasing Hormone in the Paraventricular Nucleus Are Correlated With Decreased Glucose Tolerance in Rats With Bilateral Substantia Nigra Lesions. Frontiers in Neuroscience, 2019, 13, 751.	1.4	6
68	Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF- \hat{l}^21 /Smad3 signaling pathway. Respiratory Research, 2019, 20, 163.	1.4	4
69	Diagnostic ambiguity of a uterine fibroid with abnormal appearance after severe red degeneration: A case report. International Journal of Gynecology and Obstetrics, 2019, 147, 413-414.	1.0	1
70	Impaired D2 receptor-dependent dopaminergic transmission in prefrontal cortex of awake mouse model of Parkinson's disease. Brain, 2019, 142, 3099-3115.	3.7	17
71	Pregnancy-Associated Plasma Protein A Induces Inflammatory Cytokine Expression by Activating IGF-I/PI3K/Akt Pathways. Mediators of Inflammation, 2019, 2019, 1-12.	1.4	10
72	MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways. Theranostics, 2019, 9, 945-960.	4.6	49

#	Article	IF	CITATIONS
73	Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study. Oncology Research, 2019, 27, 495-501.	0.6	26
74	Therapeutic effect of double plasma molecular adsorption system and sequential halfâ€dose plasma exchange in patients with HBVâ€related acuteâ€onâ€chronic liver failure. Journal of Clinical Apheresis, 2019, 34, 392-398.	0.7	39
75	Hepatitis�C virus nonstructural�5A protein inhibits the starvationâ€induced apoptosis of hepatoblastoma cells by increasing Beclin�1 expression. Oncology Reports, 2019, 41, 3051-3059.	1.2	2
76	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Journal of Hematology and Oncology, 2019, 12, 7.	6.9	113
77	Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations Journal of Clinical Oncology, 2019, 37, 9528-9528.	0.8	7
78	Tumor growth rate as an early indicator of the efficacy of anti-PD-1 immunotherapy in advanced melanoma Journal of Clinical Oncology, 2019, 37, e21050-e21050.	0.8	2
79	Identifying appropriate pre-pregnancy body mass index classification to improve pregnancy outcomes in women of childbearing age in Beijing, China: a retrospective cohort study. Asia Pacific Journal of Clinical Nutrition, 2019, 28, 567-576.	0.3	5
80	A clinical prognosis model for Asian advanced melanoma patients receiving immunotherapy Journal of Clinical Oncology, 2019, 37, e14081-e14081.	0.8	0
81	Mucosal melanoma staging and classification: Firstly established Journal of Clinical Oncology, 2019, 37, e21008-e21008.	0.8	O
82	Mucosal melanoma of the female genital tract: Operation modalities Journal of Clinical Oncology, 2019, 37, e21060-e21060.	0.8	1
83	Postoperative radiotherapy in resected sinonasal mucosal melanoma Journal of Clinical Oncology, 2019, 37, e21059-e21059.	0.8	0
84	Continuous intravenous infusion Rh-endostatin in combination with dacarbazine and cisplatin as the first-line therapy for metastatic melanoma Journal of Clinical Oncology, 2019, 37, e21007-e21007.	0.8	0
85	miR-185 Inhibits Fibrogenic Activation of Hepatic Stellate Cells and Prevents Liver Fibrosis. Molecular Therapy - Nucleic Acids, 2018, 10, 91-102.	2.3	31
86	Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson's disease-like pathology. Nature Communications, 2018, 9, 81.	5.8	55
87	Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. European Journal of Cancer, 2018, 100, 1-7.	1.3	31
88	Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure. Translational Oncology, 2018, 11, 1155-1159.	1.7	8
89	Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. Annals of Surgical Oncology, 2018, 25, 2184-2192.	0.7	34
90	Detection of Candida species in pregnant Chinese women with a molecular beacon method. Journal of Medical Microbiology, 2018, 67, 783-789.	0.7	8

#	Article	IF	CITATIONS
91	A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma Journal of Clinical Oncology, 2018, 36, 9528-9528.	0.8	9
92	Phase ⢠randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma Journal of Clinical Oncology, 2018, 36, 9589-9589.	0.8	18
93	Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report. Chinese Clinical Oncology, 2018, 7, 62-62.	0.4	16
94	HCBP6 upregulates human SREBP1c expression by binding to C/EBPβ-binding site in the SREBP1c promoter. BMB Reports, 2018, 51, 33-38.	1.1	5
95	Revascularization of serious atherosclerotic systemic artery stenosis caused by long-term primary hypertension. Minerva Cardioangiologica, 2018, 66, 787-790.	1.2	0
96	MicroRNA-185 induces potent autophagy via AKT signaling in hepatocellular carcinoma. Tumor Biology, 2017, 39, 101042831769431.	0.8	28
97	<scp>NS</scp> 5 <scp>ABP</scp> 37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis. Cancer Science, 2017, 108, 12-22.	1.7	4
98	Ligand- and voltage-gated Ca ²⁺ channels differentially regulate the mode of vesicular neuropeptide release in mammalian sensory neurons. Science Signaling, 2017, 10, .	1.6	34
99	<i>MAPK</i> Pathway and <i>TERT</i> Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clinical Cancer Research, 2017, 23, 6120-6127.	3.2	71
100	A single dose of cocaine potentiates glutamatergic synaptic transmission onto locus coeruleus neurons. Cell Calcium, 2017, 67, 11-20.	1.1	6
101	QiShenYiQi Pills, a Compound Chinese Medicine, Prevented Cisplatin Induced Acute Kidney Injury via Regulating Mitochondrial Function. Frontiers in Physiology, 2017, 8, 1090.	1.3	24
102	A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors Journal of Clinical Oncology, 2017, 35, 3067-3067.	0.8	1
103	A phase I clinical trial of CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma Journal of Clinical Oncology, 2017, 35, 4575-4575.	0.8	5
104	Natural killer cells as a predictive biomarker for response to anti-PD-1 therapy in patients with advanced solid tumors Journal of Clinical Oncology, 2017, 35, e21055-e21055.	0.8	0
105	Multivariate analysis of prognostic factors among 706 mucosal melanoma patients Journal of Clinical Oncology, 2017, 35, 9569-9569.	0.8	0
106	Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma Journal of Clinical Oncology, 2017, 35, e21017-e21017.	0.8	4
107	OrienX010 oncolytic viral therapy in phase Ic trial of intralesional injection in liver metastases among patients with stage IV melanoma after standard treatment Journal of Clinical Oncology, 2017, 35, e21013-e21013.	0.8	4
108	Peroxisome proliferator-activated receptor alpha acts as a mediator of endoplasmic reticulum stress-induced hepatocyte apoptosis in acute liver failure. DMM Disease Models and Mechanisms, 2016, 9, 799-809.	1.2	19

#	Article	IF	CITATIONS
109	Effects of nucleos(t)ide analogs on body composition inÂHBV-infected men: An age- and BMI-matched, cross-sectionalÂstudy. Nutrition, 2016, 32, 1206-1210.	1.1	10
110	NS5ATP6 modulates intracellular triglyceride content through FGF21 and independently of SIRT1 and SREBP1. Biochemical and Biophysical Research Communications, 2016, 475, 133-139.	1.0	6
111	OrienX010 oncolytic viral therapy in phase \tilde{A}^{c} b trial of intralesional injection in unresected stage $\tilde{A}^{c}\hat{A}^{c}$ to $\tilde{A}^{c}\hat{A}^{c}$ acral melanoma patients in China Journal of Clinical Oncology, 2016, 34, e21001-e21001.	0.8	2
112	Promotion of mitochondrial energy metabolism during hepatocyte apoptosis in a rat model of acute liver failure. Molecular Medicine Reports, 2015, 12, 5035-5041.	1.1	22
113	Transcutaneous auricular vagus nerve stimulation for pediatric epilepsy: study protocol for a randomized controlled trial. Trials, 2015, 16, 371.	0.7	19
114	Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy. International Journal of Medical Sciences, 2015, 12, 416-422.	1.1	4
115	Changes in Mitochondrial Toxicity in Peripheral Blood Mononuclear Cells During Four-Year Administration of Entecavir Monotherapy in Chinese Patients with Chronic Hepatitis B. Medical Science Monitor, 2015, 21, 2058-2063.	0.5	3
116	Clinical presentation, systemic therapy and prognosis of mucosal melanoma, a study of 463 consecutive cases Journal of Clinical Oncology, 2015, 33, e20036-e20036.	0.8	0
117	Bushen Yisui Capsule ameliorates axonal injury in experimental autoimmune encephalomyelitis. Neural Regeneration Research, 2013, 8, 3306-15.	1.6	9
118	Prevention of Contrast-Induced Nephropathy with Ascorbic Acid. Internal Medicine, 2012, 51, 531-535.	0.3	38
119	Mathematical modeling based on lamivudine switching to adefovir dipivoxil and to entecavir anti-hepatitis B infection treatment. , 2010 , , .		O